Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steve Herndon

Pulmonary Disease Charlotte, NC Medical Doctor

NPI 1861516668 CMS profile 38871

1350 S Kings Dr, Charlotte, NC 28207

Open in the dashboard

General payments

$10,796

513 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steve Herndon of Charlotte, NC is reported in the CMS Open Payments database as having received $10,796 across 513 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,461 117
2024 General $2,282 104
2023 General $2,113 98
2022 General $2,329 107
2021 General $1,254 64
2020 General $172 11
2019 General $184 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steve Herndon
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Steve Herndon were reported at $2,461. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Steve Herndon Pulmonary Disease median Middle half National median
2019 $184 $377 $109–$1,340 $163
2020 $172 $230 $56–$907 $114
2021 $1,254 $269 $68–$1,072 $132
2022 $2,329 $390 $100–$1,457 $149
2023 $2,113 $419 $114–$1,659 $160
2024 $2,282 $476 $123–$1,818 $164
2025 $2,461 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,204 113 payments
  2. GlaxoSmithKline, LLC. $1,235 65 payments
  3. Insmed, Inc. $754 35 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $691 33 payments
  5. Regeneron Healthcare Solutions, Inc. $642 25 payments
  6. Genzyme Corporation $597 26 payments
  7. Mallinckrodt Hospital Products Inc. $519 21 payments
  8. United Therapeutics Corporation $479 18 payments
  9. Amgen Inc. $398 22 payments
  10. Actelion Pharmaceuticals US, Inc. $394 21 payments
  11. Other $2,884 134 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,679 511 payments
  2. Education $117 2 payments
Products named General payments · program years 2019–2025
  1. FASENRA $825 39 payments
  2. TEZSPIRE $791 33 payments
  3. Arikayce $720 33 payments
  4. TRELEGY ELLIPTA $634 35 payments
  5. DUPIXENT Immunology $597 26 payments
  6. DUPIXENT Inflammation And Immunology $571 22 payments
  7. BREZTRI $558 24 payments
  8. NUCALA $539 25 payments
  9. ACTHAR $519 21 payments
  10. AIRSUPRA $491 22 payments
  11. Other $6,167 297 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

3,109

Median for Internal Medicine: 777

Drug cost

$1,365,243

Median for Internal Medicine: $73,373

Branded share of claims

67.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 741 $583,834
Dupixent Pen Dupilumab Brand 75 $333,142
Breo Ellipta Fluticasone/Vilanterol Brand 146 $68,598
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 91 $67,134
Spiriva Respimat Tiotropium Bromide Brand 69 $56,717
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 93 $51,449
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 50 $30,250
Spiriva Handihaler Tiotropium Bromide Brand 23 $24,107
Eliquis Apixaban Brand 23 $23,098
Symbicort Budesonide/Formoterol Fumarate Brand 65 $21,018

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$201,457

Of which drugs: $14,818

Medicare patients

1,024

Average age 75

Services billed

3,135

560 women, 464 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
COPD 46%
Ischemic heart disease 41%
Diabetes 36%
Heart failure 34%
Atrial fibrillation 33%
Chronic kidney disease 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 28 28 $2,291

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $249
  • GENZYME CORPORATION $102
$351 75 —
TYVASO
  • United Therapeutics Corporation $233
$233 — —
Arikayce
  • Insmed, Inc. $211
$211 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $195
$195 — —
NUCALA
  • GlaxoSmithKline, LLC. $194
$194 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

513 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record